Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2022

View Archived Issues

Targeting NQO1 shows protective effects in models of diabetic nephropathy

Researchers present novel capsule-mediated gastrointestinal mRNA delivery approach

Preclinical data presented for ch128.1/IgG1 in NWM hemorrhagic fever

IDP Discovery Pharma presents data on IDP-410 in preclinical glioblastoma

Antibody DH-1047 shows protection against SARS-related strains and SARS-CoV-2 variants

Heterozygous variants in the CD36 gene linked to bleeding phenotypes

Roche patents new TLR antagonists for autoimmune disease

Researchers divulge SSTR4 agonists for treatment of pain

Beijing Tide Pharmaceutical synthesizes new ATR kinase inhibitors

Chiesi Farmaceutici identifies new TGFBR1 inhibitors for IPF

Wuhan LL Science and Technology Development presents new ROCK inhibitors

In vitro data show proof of concept for Theralase SARS-CoV-2 vaccine

Navidea sponsors research at Penn to evaluate Tc99m tilmanocept as prognostic marker in glioblastoma

Novel PSCA CAR_s15 NK cell immunotherapy prolongs survival in pancreatic cancer model

Researchers publish data on VIP-236 as a promising antitumoral agent

Three components enable 3D kidney tissue from mouse embryonic stem cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.